Introduction: Patients with locally advanced rectal cancer (LARC) who are unfit for chemoradiation (CRT), are often offered short-course radiotherapy followed by delayed surgery (SCRT-delay). This entails a lower radiation dose, no chemotherapy and a shorter treatment period. This may lower their chances for complete tumor response and, as such, organ-sparing approaches. The purpose of this study was to compare the pathological complete response (pCR) rates between neoadjuvant CRT and SCRT-delay in patients with LARC in a nationwide database from the Netherlands. Methods: In the population based Netherlands Cancer Registry, clinical stage III rectal cancer patients, diagnosed between 2008 and 2014, who underwent CRT or SCTR-delay were selec...
Objective: To investigate differences in postoperative outcomes between short-course radiotherapy an...
Introduction: The addition of induction chemotherapy (ICT) to neoadjuvant chemoradiotherapy (CRT) ha...
PURPOSE: In selected patients, a wait-and-see strategy after chemoradiotherapy for rectal cancer mig...
Introduction: Patients with locally advanced rectal cancer (LARC) who are unfit for chemoradiation (...
Background: To retrospectively evaluate the difference in terms of pathologic complete response (pCR...
Aim The aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' ...
Background: To retrospectively evaluate the difference in terms of pathologic complete response (pCR...
International audiencePurpose A pathologic complete response (pCR; ypT0N0) of a rectal tumor after n...
Complete pathological response (pCR) is achieved in 10–20% of rectal cancers when treated with short...
PURPOSE:Neoadjuvant therapy is able to reduce local recurrence in rectal cancer. Immediate surgery a...
Aims: The aim of this study was to define a potential benefit of pathological complete response rate...
Neoadjuvant therapy is the gold standard treatment of locally advanced rectal cancer. It may induce ...
Introduction: The addition of induction chemotherapy (ICT) to neoadjuvant chemoradiotherapy (CRT) ha...
Objective: To investigate differences in postoperative outcomes between short-course radiotherapy an...
Introduction: The addition of induction chemotherapy (ICT) to neoadjuvant chemoradiotherapy (CRT) ha...
PURPOSE: In selected patients, a wait-and-see strategy after chemoradiotherapy for rectal cancer mig...
Introduction: Patients with locally advanced rectal cancer (LARC) who are unfit for chemoradiation (...
Background: To retrospectively evaluate the difference in terms of pathologic complete response (pCR...
Aim The aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' ...
Background: To retrospectively evaluate the difference in terms of pathologic complete response (pCR...
International audiencePurpose A pathologic complete response (pCR; ypT0N0) of a rectal tumor after n...
Complete pathological response (pCR) is achieved in 10–20% of rectal cancers when treated with short...
PURPOSE:Neoadjuvant therapy is able to reduce local recurrence in rectal cancer. Immediate surgery a...
Aims: The aim of this study was to define a potential benefit of pathological complete response rate...
Neoadjuvant therapy is the gold standard treatment of locally advanced rectal cancer. It may induce ...
Introduction: The addition of induction chemotherapy (ICT) to neoadjuvant chemoradiotherapy (CRT) ha...
Objective: To investigate differences in postoperative outcomes between short-course radiotherapy an...
Introduction: The addition of induction chemotherapy (ICT) to neoadjuvant chemoradiotherapy (CRT) ha...
PURPOSE: In selected patients, a wait-and-see strategy after chemoradiotherapy for rectal cancer mig...